Zolpidem 10mg Film-Coated Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Zolpidem 10 mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains: 10 mg zolpidem tartrate, equivalent to 8.038 mg zolpidem.
Excipient(s): Each tablet contains 47.55 mg lactose monohydrate.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablet
White, round, biconvex film-coated tablet with score line on one side
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Zolpidem is indicated for short-term treatment of insomnia in adults in situations where the insomnia is debilitating or is causing severe distress for the patient.
4.2 Posology and method of administration
For oral use
The medicinal product should be taken with fluid just before going to bed.
The duration of treatment should be as short as possible. In general it should be a few days to two weeks with a maximum, including the tapering off process, of four weeks.
The tapering off process should be tailored to the individual.
In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient's status.
Adults:
The treatment should be taken in a single intake and not be re-administered during the same night.
The recommended daily dose for adults is 10 mg to be taken immediately at bedtime. The lowest effective daily dose of zolpidem should be used and must not exceed 10 mg.
Older people:
In elderly or debilitated patients who may be especially sensitive to the effects of zolpidem a dose of 5 mg is recommended. This dose should only be increased to 10 mg where the clinical response is inadequate and the medicinal product is well tolerated.
Patients with hepatic impairment
Patients with hepatic impairment who do not clear the medicinal product as rapidly as normal individuals, a dose of 5 mg is recommended. This dose should only be increased to 10 mg where the clinical response is inadequate and the medicinal product is well tolerated.
The total dose of zolpidem should not exceed 10 mg in any patient.
Paediatric population
Zolpidem is not recommended for use in children and adolescents below 18 years of age, due to
a lack of data to support use in this age group. The available evidence from placebo-controlled
clinical trials is presented in section 5.1.
4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Myasthenia gravis
• Severe respiratory depression
• Obstructive sleep apnoea
• Severe hepatic insufficiency
• In the absence of data, zolpidem should not be prescribed for children (See section 4.2 and section 5.1)
4.4 Special warnings and precautions for use
General
The cause of insomnia should be identified wherever possible. The underlying factors should be treated before a hypnotic is prescribed. The failure of insomnia to remit after a 7-14 day course of treatment may indicate the presence of a primary psychiatric or physical disorder, which should be evaluated.
General information relating to effects seen following administration of benzodiazepines or other hypnotic agents which should be taken into account by the prescribing physician are described below.
Next-day psychomotor impairment
The risk of next-day psychomotor impairment, including impaired driving ability, is increased if:
- zolpidem is taken within less than 8 hours before performing activities that require mental alertness (see section 4.7);
- a dose higher than the recommended dose is taken;
- zolpidem is co-administered with other CNS depressants or with other drugs that increase the blood levels of zolpidem, or with alcohol or illicit drugs (see section 4.5). Zolpidem should be taken in a single intake immediately at bedtime and not be readministered during the same night.
Tolerance
Some loss of efficacy to the hypnotic effects of short-acting benzodiazepines and benzodiazepine-like agents may develop after repeated use for a few weeks.
Dependence
Use of benzodiazepines or benzodiazepine-like agents may lead to the development of physical and psychological dependence of these products. The risk of dependence increases with dose and duration of treatment and is also greater in patients with a history of psychiatric disorders and/or alcohol or medicinal product abuse.
Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms. These may consist of headaches or muscle pain, extreme anxiety and tension, restlessness, confusion and irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.
Rebound insomnia
A transient syndrome whereby the symptoms that led to treatment with a benzodiazepines or benzodiazepine-like agent recur in an enhanced form, may occur on withdrawal of hypnotic agent. It may be accompanied by other reactions including mood changes, anxiety and restlessness.
It is important that the patient should be aware of the possibility of rebound phenomena, thereby minimising anxiety over such symptoms should they occur when the medicinal product is being discontinued.
There are indications that, in the case of benzodiazepines and benzodiazepine-like agents with a short duration of action, withdrawal phenomena can become manifest within the dosage interval, especially when the dosage is high.
As the risk of withdrawal symptoms/rebound phenomena are more likely to develop after abrupt discontinuation of treatment, it is recommended to decrease the dose gradually.
Duration of treatment
The duration of treatment should be as short as possible (see section 4.2), but should not exceed 4 weeks including the tapering off process. Extension beyond these periods should not take place without re-evaluation of the situation.
It may be useful to inform the patient when treatment is started that it will be of limited duration.
Amnesia
Benzodiazepines or benzodiazepine-like agents may induce anterograde amnesia. The condition usually occurs several hours after ingesting the product.
In order to reduce the risk, patients should ensure that they will be able to have an uninterrupted sleep of 8 hours (see section 4.8).
Psychiatric and "paradoxical" reactions
When using benzodiazepines or benzodiazepine-like agents, reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, somnambulism, inappropriate behaviour, increased insomnia and other adverse behavioural effects are known to occur. Should this occur, use of the product should be discontinued. These reactions are more likely to occur in the elderly.
Specific patient groups
Elderly or debilitated patients should receive a lower dose: see recommended dosage (section 4.2).
Due to the myorelaxant effect there is a risk of falls and consequently of hip fractures particularly for elderly patients when they get up at night.
Patients with renal insufficiency (see section 5.2)
Although dose adjustment is not necessary, caution should be exercised.
Patients with chronic respiratory insufficiency
Caution should be observed when prescribing zolpidem since benzodiazepines have been shown to impair respiratory drive. It should also be taken into consideration that anxiety or agitation have been described as signs of decompensated respiratory insufficiency.
Patients with severe hepatic impairment
Benzodiazepines and benzodiazepine-like agents are not indicated for the treatment of patients with severe hepatic impairment as they may precipitate encephalopathy.
Use in patients with psychotic illness:
Benzodiazepines and benzodiazepine-like agents are not recommended for the primary treatment.
Use in depression:
Despite the fact that relevant clinical, pharmacokinetic and pharmacodynamic interactions with SSRI have not been demonstrated, zolpidem should be administered with caution in patients exhibiting symptoms of depression. Suicidal tendencies may be present. Due to the possibility of intentional overdose by the patient, the lowest amount of medicinal product that is feasible should be supplied to these patients.
Benzodiazepines and benzodiazepine-like agents should not be used alone to treat depression or anxiety associated with depression (suicide may be precipitated in such patients).
Use in patients with a history of drug or alcohol abuse:
Benzodiazepines and benzodiazepine-like agents should be used with extreme caution in patients with a history of alcohol or drug abuse. These patients should be under careful surveillance when receiving zolpidem since they are at risk of habituation and psychological dependence.
Somnambulism and associated behaviours:
Sleep walking and other associated behaviours such as “sleep driving”, preparing and eating food, making phone calls or having sex, with amnesia of the event, have been reported in patients who had taken zolpidem and were not fully awake. The use of alcohol and other CNS-depressants with zolpidem appears to increase the risk of such behaviours, as does the use of zolpidem at doses exceeding the maximum recommended dose. Discontinuation of zolpidem should be strongly considered for patients who report such behaviours (See section
4.5 and section 4.8).
The medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Concomitant intake with alcohol is not recommended. The sedative effect may be enhanced when the product is used in combination with alcohol. This affects the ability to drive or use machines.
Combination with CNS depressants
Enhancement of the central depressive effect may occur in cases of concomitant use with antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, antiepileptic drugs, anaesthetics and sedative antihistamines. Therefore, concomitant use of zolpidem with these drugs may increase drowsiness and next-day psychomotor impairment, including impaired driving ability (see section 4.4 and section 4.7). Also, isolated cases of visual hallucinations were reported in patients taking zolpidem with antidepressants including bupropion, desipramine, fluoxetine, sertraline and venlafaxine.
Co- administration of fluvoxamine may increase blood levels of zolpidem, concurrent use is not recommended.
Co-administration of muscle relaxants may potentiate the muscle-relaxant effect - especially in elderly patients and at higher dosage (risk of falling!).
In the case of narcotic analgesics enhancement of euphoria may also occur leading to an increase in psychological dependence.
CYP450 inhibitors and inducers
Zolpidem is metabolised by some enzymes of the cytocrome P450-family. The main enzyme is CYP3A4.
Rifampicin induces the metabolism of zolpidem, resulting in approximately 60% reduction in peak plasma concentrations and possibly decreased efficacy. Similar effects might be expected also with other strong inducers of cytochrome P450-enzymes (e.g. carbamazepine, and phenytoin).
Co- administration ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.
Compounds that inhibit hepatic enzymes particularly CYP3A4 (e.g. azole antimycotics, macrolide antibiotics, and grapefruit juice) may increase plasma concentrations and enhance the activity of zolpidem. However, when zolpidem is administrated with itraconazol (CYP3A4 inhibitor), the pharmacokinetic and pharmacodynamic effects are not significantly different. The clinical relevance of these results is unknown.
Co-administration of zolpidem with ketoconazole (200mg twice daily), a potent CYP3A4 inhibitor, prolonged zolpidem elimination half-life, increased total AUC, and decreased apparent oral clearance when compared to zolpidem plus placebo. The total AUC for zolpidem was increased modestly, when co-administered with ketoconazole, it increased by a factor of 1.83 when compared to zolpidem alone. A routine dosage adjustment of zolpidem is not considered necessary, but patients should be advised that use of zolpidem with ketoconazole may enhance the sedative effects.
Other drugs
When zolpidem was administered with warfarin, digoxin, ranitidine, no significant pharmacokinetic interactions were observed.
4.6 Fertility, Pregnancy and lactation
Pregnancy
There are insufficient data to permit an assessment of the safety of Zolpidem during pregnancy.
Although animal studies have shown no teratogenic or embryotoxic effects, safety in pregnancy has not been established in humans.
Caution should be exercised when prescribing to pregnant women.
If the product is prescribed to a woman of childbearing potential, she should be warned to contact her physician regarding discontinuance of the product if she intends to become or suspect that she is pregnant.
If, for compelling medical reason, zolpidem is administered during the late phase of pregnancy, or during labour, effects on the neonate, such as hypothermia, hypotonia and moderate respiratory depression, can be expected due to the pharmacological action of the product.
Infants born to mothers who took benzodiazepines or benzodiazepine-like agents chronically during the latter stages of pregnancy may develop withdrawal symptoms in the postnatal period as a result of physical dependence.
Breast-feeding
Zolpidem passes into breast milk in minimal amounts. Zolpidem should therefore not be used during breast-feeding since effects on the infant have not been investigated.
Fertility:
In a rat reproduction study, there was no effect on fertility in males or females after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/m2.
4.7 Effects on ability to drive and use machines
Zolpidem has major influence on the ability to drive and use machines.
Vehicle drivers and machine operators should be warned that, as with other hypnotics, there may be a possible risk of drowsiness, prolonged reaction time, dizziness, sleepiness, blurred/double vision and reduced alertness and impaired driving the morning after therapy (see section 4.8). In order to minimise this risk a resting period of at least 8 hours is recommended between taking zolpidem and driving, using machinery and working at heights. Driving ability impairment and behaviours such as ‘sleep-driving’ have occurred with zolpidem alone at therapeutic doses.
Furthermore, the co-administration of zolpidem with alcohol and other CNS depressants increases the risk of such behaviours (see section 4.4 and 4.5). Patients should be warned not to use alcohol or other psychoactive substances when taking zolpidem.
4.8 Undesirable effects
The following frequency data is the basis for the evaluation of undesirable effects:
Very common (>1/10)
Common (>1/100 to < 1/10)
Uncommon (>1/1,000 to < 1/100)
Rare (>1/10,000 to < 1/1,000)
Very rare (< 1/10,000)
Not known (cannot be estimated based on available data).
There is evidence of a dose-relationship for adverse effects associated with zolpidem use, particularly for certain CNS and gastrointestinal events.
These effects seem to be related with individual sensitivity and to appear more often within the hour following the medicinal product intake if the patient does not go to bed or does not sleep immediately (see section 4.2).
Immune system disorders
Not known: angioneurotic oedema
Psychiatric disorders
Common: hallucination, agitation, nightmare Uncommon: confusional state, irritability
Not known: restlessness, aggression, delusion, anger, psychosis, abnormal behaviour, sleep walking (See Section 4.4), dependence (withdrawal symptoms, or rebound effects may occur after treatment discontinuation), libido disorder
Most of these psychiatric undesirable effects are related to paradoxical reactions
Nervous system disorders:
Common: somnolence, headache, dizziness, exacerbated insomnia, anterograde amnesia: (amnestic effects may be associated with inappropriate behaviour)
Not known: depressed level of consciousness
Eye disorders Uncommon: diplopia
Gastro-intestinal Disorders Common: diarrhoea
Hepatobiliary disorders
Not known: Liver enzymes elevated
Skin and subcutaneous tissue disorders Not known: rash, pruritus, urticaria
Musculoskeletal and connective tissue disorders Not known: muscular weakness
General disorders and administration site conditions Common: fatigue
Not known: gait disturbance, drug tolerance, fall (predominantly in elderly patients and when zolpidem was not taken in accordance with prescribing recommendation)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:
Yellow Card Scheme
Website: www.mhra.gov .uk/yellowcard
4.9 Overdose
In reports of overdose with zolpidem alone, impairment of consciousness has ranged from somnolence to light coma. Besides visual disturbances, dystonia, ataxia and paradoxical reactions (restlessness, hallucinations) may occur.
Individuals have fully recovered from overdoses up to 400 mg of zolpidem, 40 times the recommended dose.
General symptomatic and supportive measures should be used. Immediate gastric lavage should be used where appropriate. Intravenous fluids should be administered as needed. If there is no advantage in emptying the stomach, activated charcoal should be given to reduce absorption. Monitoring of respiratory and cardiovascular functions should be considered. Sedating drugs should be withheld even if excitation occurs.
Use of flumazenil may be considered when serious symptoms are observed. In the treatment of overdose with any medicinal product, it should be borne in mind that multiple agents may have been taken.
Due to the high distribution volume and protein binding of zolpidem, haemodialysis and forced diuresis are not effective measures. Hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Hypnotics and Sedatives, Benzodiazepine related drugs ATC Code: N05C F02
Zolpidem, an imidazopyridine is a benzodiazepine-like hypnotic agent. In experimental studies it was shown that it has sedative effects at lower dosages than those required to exert anticonvulsant, myorelaxant or anxiolytic effects. These effects are related to a specific agonist action at central receptors belonging to the ”GABA-omega” (BZ1 & BZ2) macromolecular receptor” complex, modulating the opening of the chloride ion channel. Zolpidem acts primarily upon omega (BZ1) receptor subtypes. The clinical relevance of this is not known.
The randomized trials only showed convincing evidence of efficacy of 10mg zolpidem.
In a randomized double-blind trial in 462 non-elderly healthy volunteers with transient insomnia, zolpidem 10mg decreased the mean time to fall asleep by 10 minutes compared to placebo, while for 5mg zolpidem this was 3 minutes.
In a randomized double-blind trial in 114 non-elderly patients with chronic insomnia, zolpidem 10mg decreased the mean time to fall asleep by 30 minutes compared to placebo, while for 5mg zolpidem this was 15 minutes.
In some patients, a lower dose of 5 mg could be effective.
Paediatric population
Safety and efficacy of zolpidem have not been established in children aged less than 18 years. A randomized placebo-controlled study in 201 children aged 6-17 years with insomnia associated with Attention Deficit Hyperactivity Disorder (ADHD) failed to demonstrate efficacy of zolpidem 0.25 mg/kg/day (with a maximum of 10 mg/day) as compared to placebo. Psychiatric and nervous system disorders comprised the most frequent treatment emergent adverse events observed with zolpidem versus placebo and included dizziness (23.5% versus 1.5%), headache (12.5% versus 9.2%), and hallucinations (7.4% versus 0%) (see sections 4.2 and 4.3).
5.2 Pharmacokinetic properties
Absorption
Zolpidem has both a rapid absorption and onset of hypnotic effect.
Bioavailability is 70% following oral administration. It demonstrates linear kinetics in the therapeutic dose range. The therapeutic plasma level is between 80 and 200 ng/ml. Peak plasma concentration is reached at between 0.5 and 3 hours after administration.
Distribution
The distribution volume in adults is 0.54 l/kg and decreases to 0.34 l/kg in the elderly.
Protein binding amounts to 92%. First pass metabolism by the liver amounts to approximately 35%. Repeated administration has been shown not to modify protein binding indicating a lack of competition between zolpidem and its metabolites for binding sites.
Elimination
The elimination half-life is short, with a mean of 2.4 hours.
All metabolites are pharmacologically inactive and are eliminated in the urine (56%) and in the faeces (37%).
Zolpidem has been shown in trials to be non-dialysable.
Other special populations
In patients with renal insufficiency, a moderate reduction in clearance is observed (independent of possible dialysis). The other pharmacokinetic parameters remain unaffected.
In elderly patients a reduced clearance has been observed. In a group of patients aged 81-95 years, the maximal plasma concentrations increased by around 80 % without a significant change in the elimination half-life.
In patients with liver cirrhosis a 5-fold increase in AUC and a 3-fold increase in half-life was observed.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, cancerogenic potential, toxicity to reproduction and development.
Foetal developmental retardations and foetotoxic effects in rats and rabbits were observed only at doses well above the maximum human dosage. There was no evidence of a teratogenic potential.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose, monohydrate
Cellulose, microcrystalline
Sodium starch glycolate type A
Hypromellose
Magnesium stearate
Opadry white Y-1-7000, containing:
Hypromellose Macrogol 400 Titanium dioxide E 171
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
5 (five) years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions. Store in the original package to protect from light.
6.5 Nature and contents of container
The film-coated tablets are packed in PVC clear /Al press-through blister. Pack size of 10, 20 and 100 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
ALKALOID-INT d.o.o.
Slandrova ulica 4 1231 Ljubljana-Crnuce Slovenia
8 MARKETING AUTHORISATION NUMBER(S)
PL 34088/0004
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
13/12/2011
10 DATE OF REVISION OF THE TEXT
08/03/2016